- Home
- NAMS
as 11-21-2024 4:00pm EST
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
| Founded: | 2019 | Country: | Netherlands |
| Employees: | N/A | City: | NARRDEN |
| Market Cap: | 2.3B | IPO Year: | N/A |
| Target Price: | $33.80 | AVG Volume (30 days): | 634.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.21 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.90 - $26.35 | Next Earning Date: | 11-06-2024 |
| Revenue: | $33,594,000 | Revenue Growth: | 78.77% |
| Revenue Growth (this year): | -7.4% | Revenue Growth (next year): | -50.25% |
Latest NewAmsterdam Pharma Company N.V. News
NAMS Breaking Stock News: Dive into NAMS Ticker-Specific Updates for Smart Investing
TipRanks
9 hours ago
NewAmsterdam Pharma Reports Promising Phase 3 Trial Results
Investor's Business Daily
a day ago
NewAmsterdam Dives — And Sacrifices A Cup Base — Despite A Winning Cholesterol Study
GlobeNewswire
a day ago
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH
GlobeNewswire
3 days ago
NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024
Simply Wall St.
10 days ago
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Shares Could Be 46% Below Their Intrinsic Value Estimate
GlobeNewswire
15 days ago
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
GlobeNewswire
20 days ago
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
24 days ago
NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November
Compare NAMS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NAMS NewAmsterdam Pharma Company N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.